User: Guest

  



DOMAIN EXPERT ENGAGEMENTS

Number of executives repeatedly engaged by snail & email outreach*

POOL + OUTREACH

9086

Interactions with Platform & by Email *

INTERACTIONS

1272

Unique # Participated *

PARTICIPANTS

273

Responses Validated *

VALIDATIONS

52

* Platform engagements are dynamic. Stats are published quarterly.


  •  CODE

  •  PAGES

  •  DATE

  •  PRICE

    $

  •  DATA EXHIBITS

    125


TABLE OF CONTENTS


   Pages :    | $

   Study Reliability and Reporting Limitations.....I-1  
   Disclaimers.....I-2
Data Interpretation & Reporting Level.....I-2
  
   Product Definitions and Scope of Study.....I-3  
   Introduction.....II-1
Anti-Infective Drugs – Mechanism of Action.....II-1
Increasing Drug Resistance – A Major Challenge to Reckon With.....II-1
Antibacterial Resistance Costs High.....II-1
Novel Approaches to Combat Drug-Resistant Strains.....II-1
1$100
   Combination Therapy.....II-2
New Approach to Directly Target Illness Rather than Infection.....II-2
Antivirals Directed at Human Targets.....II-2
Immunomodulation.....II-2
Antivirulence.....II-2
Select Companies Involved in Anti-Virulence Drug Research.....II-2
1$100
   Pipeline Analysis of Anti-Infectives by Therapeutic Class.....II-3
Table 1: Anti-Infectives Pipeline by Therapeutic Class and Development Stage:(includes corresponding Graph/Chart).....II-3
Injectables Gain Traction.....II-3
1$350
   Market Outlook.....II-4
Anti-Bacterials Drive Global Anti-Infectives Market.....II-4
Table 2: World Market for Anti-Infectives (2008): Percentage Share Breakdown of Value Sales by Therapeutic Class - Anti-Bacterials, Anti-Virals, Anti-Fungals, and Others (includes corresponding Graph/Chart).....II-4
1$350
   Anti-Virals – A Significant Market.....II-5
Original Brands Leads the Supreme.....II-5
Table 3: Global Market for Anti-Infectives by Licensing Status (2006-07): Percentage Share Breakdown of Value Sales for Branded, Licensed Brands, Unbranded Drugs, and Other Drugs (includes corresponding Graph/Chart).....II-5
United States - The Largest Anti-infectives Market Globally.....II-5
1$350
   Table 4: World Market for Anti-Infectives by Geographic Region (2010): Percentage Share Breakdown for US, Japan, Europe, and Rest of World (includes corresponding Graph/Chart).....II-6

Table 5: World Market for Anti-Infectives: Breakdown of Select Geographic Regions/Country by Value Growth Potential for the Period 2006-2015 (includes corresponding Graph/Chart).....II-6
Europe – The Second Leading Worldwide Market for Anti-Infectives.....II-6
Competitive Landscape.....II-6
1$350
   Table 6: Worldwide Anti-Infectives Market by Leading Players (2007): Percentage Share Breakdown of Value Sales for Glaxo SmithKline, Merck, Pfizer, Novartis, Gilead Sciences, Abbott, Wyeth, Sanofi-Aventis, Bristol-Myers Squibb, Johnson & Johnson (includes corresponding Graph/Chart).....II-71$350
   Table 7: Leading Anti-Infective Companies Worldwide and their Brands: Value Sales for the year 2008 (includes corresponding Graph/Chart).....II-81$350
   GlaxoSmithKline Portfolio of Anti-Infectives - Breakdown by Therapeutic Class.....II-91$100
   Market Estimates and Forecasts.....II-10
Market Analysis by Drug Class.....II-10
Table 8: Worldwide Market for Anti-Bacterials by Major Drug Class (2008): Percentage Share Breakdown for Cephalosporins, Macrolides, Fluoroquinolones, Penicillins, and Others (includes corresponding Graph/Chart).....II-10
Market Analysis by Region.....II-10
1$350
   Competition in Anti-Bacterials Market.....II-11
Table 9: World Anti-Bacterials Market (2008): Break-Up of Value Sales (in US$ Billion) for Leading Drugs (includes corresponding Graph/Chart).....II-11
1$350
   Global Market Outlook.....II-12
Antibacterial Resistance – A Key Growth Dampener.....II-12
Antibiotic-Resistant Bacteria by Type.....II-12
Bacterial Resistance to Most Commonly Used Antibacterial Drug Class: Incidence
  Level in Select Countries.....II-12
1$100
   Generic Competition Intensifies.....II-13
Patent Expiries Commoditize Antibiotics.....II-13
Patent Expiries of Major Anti-Bacterial Drugs.....II-13
1$100
   R&D Initiatives Imperative for Developing Novel Drugs to Combat Drug-Resistant
  Strains.....II-14
Hospital Market for Gram-Positive Antibacterials to Witness Encouraging Gains.....II-14
Anti-MRSA Antibiotics Find Their Way.....II-14
1$100
   What are Anti-bacterials?.....II-15
Taxonomy of Anti-bacterials.....II-15
1$100
   Classification of Anti-bacterials based on Mechanism of Action.....II-16
Antibacterial Drug Classes.....II-16
Penicillin.....II-16
Cephalosporins.....II-16
1$100
   Side Effects.....II-17
Fluroquinolones.....II-17
Side Effects.....II-17
Tetracyclines.....II-17
Treatment.....II-17
Side Effects.....II-17
1$100
   Macrolides.....II-18
Treatment.....II-18
Side Effects.....II-18
Others.....II-18
Classification based on the Process of Suppressing or Killing Bacteria.....II-18
Bactericidal or Bacteria Destroying Drugs.....II-18
Bacteriostatic Drugs.....II-18
1$100
   Bacterial Spectrum.....II-19
Use of Antibacterial Drugs: An Overview.....II-19
Phage Therapy, a Promising Approach for Bacterial Infections.....II-19
How Does Phage Therapy Works?.....II-19
1$100
   Treatment and Application of Phase Therapy.....II-20
Phages for Antibiotic-Resistant Bacteria.....II-20
Companies Involved in Phage Therapy Research.....II-20
1$100
   Market Estimates and Forecasts.....II-21
Five Major Anti-Virals Dominate the Antivirals Market.....II-21
Players Active in Anti-Virals Market.....II-21
1$100
   Table 10: Major Anti-Viral Drugs of GSK and Bristol-Myers Squibb: Annual Sales for the year 2008 (includes corresponding Graph/Chart).....II-22
Market Leaders In 2008: A Review.....II-22
1$350
   Table 11: World Anti-Virals Market (2008): Break-Up of Value Sales (in US$ Billion) For Leading Drugs (includes corresponding Graph/Chart).....II-23
Key Trends and Issues.....II-23
Preventative Antivirals Gain Significance.....II-23
1$350
   Table 12: Global Market for Anti-Virals (2007): Percentage Share Breakdown by Category - Antiviral Therapeutics, Vaccines, Monoclonal Antibodies, and Others (includes corresponding Graph/Chart).....II-24
R&D Initiatives Abound in Antivirals Market.....II-24
1$350
   Companies Involved in Late-Stage Development of Anti-virals.....II-25
Companies Involved in Phase II Clinical Studies of Anti-virals.....II-25
Companies Involved in Phase I Clinical Studies of Anti-virals.....II-25
1$100
   Select Companies in Pre-clinical Development Phase of Anti-virals.....II-26
Development of Direct Targeted Antiviral Therapies.....II-26
New Novel Anti-Viral Peptides.....II-26
siRNA Shows Antiviral Potential.....II-26
1$100
   Combination Drug Therapy Gains Popularity.....II-27
Microbiocides, a New Way to Fight STD and HIV Infections.....II-27
1$100
   What are Anti-Virals?.....II-28
Emergence of Antivirals.....II-28
Types of Antivirals.....II-28
Entry Blockers.....II-28
1$100
   Drugs in the Market.....II-29
Viral Component Replication Blockers.....II-29
Viral Component Assimilation Blockers.....II-29
Antisense Molecules.....II-29
Synthetic Ribozymes.....II-29
Protease Inhibitors.....II-29
1$100
   Blockers for Release of Completed Viruses from the Host Cell.....II-30
Other Types of Antivirals.....II-30
Interferons.....II-30
Synthetic Monoclonal Antibodies.....II-30
Major Viral Infections & Related Drugs.....II-30
Human Immunodeficiency Virus (HIV).....II-30
1$100
   HIV Treatment – The Largest in Anti-Virals Sector.....II-31
Major Anti-HIV/AIDS Drugs by Category.....II-31
Nucleoside Reverse Transcriptase Inhibitors (NRTIs).....II-31
1$100
   Major Nucleoside Reverse Transcriptase Inhibitors (NRTIs):.....II-32
Epivir (Lamivudine).....II-32
Retrovir (Zidovudine).....II-32
Combivir (Epivir+Retrovir).....II-32
Videx (Didanosine).....II-32
Zerit (Stavudine).....II-32
1$100
   Hivid (Zalcitabine).....II-33
Protease Inhibitors (PIs).....II-33
Major Protease Inhibitors:.....II-33
Norvir (Ritonavir).....II-33
Kaletra (Lopinavir+Ritonavir).....II-33
Invirase (Saquinavir).....II-33
1$100
   Fosamprenavir.....II-34
Integrase Inhibitors (IIs).....II-34
ISENTRESS.....II-34
Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs).....II-34
Entry Blockers.....II-34
Fusion Inhibitors.....II-34
Fuzeon (Enfuvirtide).....II-34
1$100
   Antiviral siRNAs.....II-35
Drugs for HIV Infected Patients in Advanced Stage.....II-35
Combination Therapies For HIV Infected Patients.....II-35
Hepatitis Infection.....II-35
Acute and Chronic Hepatitis Infections.....II-35
Treatment Regimen for Hepatitis Infection.....II-35
1$100
   Interferons.....II-36
Standard Interferons.....II-36
Pegylated Interferons.....II-36
1$100
   Ribavirin.....II-37
Types of Hepatitis Infection based on Strains.....II-37
Hepatitis A Virus (HAV) Infection.....II-37
Hepatitis B Virus (HBV) Infection.....II-37
Treatment for Chronic HBV Infection.....II-37
Vaccines Dominate the Category.....II-37
1$100
   Antiviral Drugs for Chronic HBV Infection.....II-38
Major Anti-HBV Drugs:.....II-38
Hepatitis C Virus (HCV) Infection.....II-38
Treatment for Chronic Hepatitis C Infection.....II-38
1$100
   Some Alternative Treatments.....II-39
Drugs in Pipeline:.....II-39
Hepatitis C - Drugs in Pipeline as on March 2008.....II-39
1$100
   Hepatitis D Virus (HDV) Infection.....II-40
Hepatitis E Virus (HEV) Infection.....II-40
Herpes Simplex Virus (HSV) Infection.....II-40
Treatment for HSV Infection.....II-40
1$100
   Major HSV Drugs Worldwide and their Patent Expiries.....II-41
Antivirals for HSV Infection.....II-41
Select HSV Infection Drugs.....II-41
Zovirax (Aciclovir).....II-41
Famvir (Famciclovir).....II-41
1$100
   Foscavir (Foscarnet).....II-42
Valtrex (Valaciclovir).....II-42
Vectavir/Denavir (Penciclovir).....II-42
Abreva (Docosanol).....II-42
Ophthalmic Viral Infections & Related Drugs.....II-42
Cytovene (Ganciclovir).....II-42
Vistide (Cidofovir).....II-42
Foscavir (Foscarnet).....II-42
1$100
   Human Papilloma Virus (HPV).....II-43
Treatment for HPV Infection.....II-43
Respiratory Viruses Infections.....II-43
Influenza Virus.....II-43
Treatment for Influenza.....II-43
Major Influenza Drugs Profile.....II-43
Symmetrel® (Amantadine).....II-43
1$100
   Flumadine (Rimantadine).....II-44
Tamiflu (Oseltamivir).....II-44
Relenza (Zanamivir).....II-44
Respiratory Syncytial Virus (RSV) Infection.....II-44
Treatment for RSV and other Respiratory Viral Infections.....II-44
Other Types of Viral Diseases.....II-44
Treatment for Other Viral Diseases.....II-44
1$100
   Anti-Fungals Market – A Quick Review.....II-45
Current and Future Analysis.....II-45
Anti-fungals: An Introduction.....II-45
Classification of Anti-Fungal Drugs by Class.....II-45
1$100
   Allylamines.....II-46
Select Systemic and Topical Anti-Fungal Drugs Classified under Allylamines
  Group.....II-46
Azoles.....II-46
Select Systemic and Topical Anti-Fungal Drugs Classified under Azoles Group.....II-46
1$100
   Polyene Macrolides.....II-47
Select Systemic and Topical Anti-Fungal Drugs Classified under Polyene Macrolides
  Group.....II-47
Others.....II-47
Other Systemic and Topical Anti-Fungal Drugs.....II-47
Fungal Infections & Treatment.....II-47
Aspergillosis – Disease & Symptoms.....II-47
1$100
   General Syndromes of Aspergillosis & Treatment Options.....II-48
Pulmonary Aspergillosis.....II-48
Aspergilloma.....II-48
Invasive Aspergillosis.....II-48
Select Drugs Used for the Treatment of Invasive Aspergillosis.....II-48
1$100
   Blastomycosis – Disease & Symptoms.....II-49
Blastomycosis Treatment: Azoles the Preferred Choice.....II-49
Select Drugs or Medications Used For Blastomycosis Fungal Infection
  Treatment.....II-49
1$100
   Candidiasis – Disease & Symptoms.....II-50
General Syndromes of Candidiasis & Treatment Options.....II-50
Mucocutaneous Candidiasis.....II-50
1$100
   Treatment Options.....II-51
Select Drugs or Medications Used for the Treatment of Cutaneous
  Candidiasis.....II-51
1$100
   Invasive Candidiasis.....II-52
Treatment Options.....II-52
Cryptococcosis & Clinical Syndromes.....II-52
1$100
   Treatment of Cryptococcosis.....II-53
Select Drugs Used for the Treatment of Cryptococcosis.....II-53
Histoplasmosis – Disease and Symptoms.....II-53
1$100
   Treatment Options for Histoplasmosis.....II-54
Select Drugs Used for the Treatment of Histoplasmosis.....II-54
1$100
   Introduction.....II-55
Serum Institute of India Ltd. – A Major Player in Vaccines Market.....II-55
Other Major Players Active in Vaccines Market.....II-55
1$100
   Table 13: Vaccines Portfolio of GlaxoSmithKline and Merck: Breakdown of Annual Sales (in US$ Million) for the year 2008 (includes corresponding Graph/Chart).....II-56
Select Infectious Diseases and Vaccines.....II-56
Infectious Diseases.....II-56
Diphtheria.....II-56
1$350
   Tetanus (Lockjaw).....II-57
Pertussis (Whooping Cough).....II-57
Vaccines for Diphtheria, Tetanus and Pertussis.....II-57
Select Diphtheria Vaccines by Company.....II-57
1$100
   DTaP – A Combination Vaccine for Diphtheria, Tetanus and Pertussis.....II-58
DT - A Combination Vaccine for Diphtheria and Tetanus.....II-58
Td - The Tetanus and Diphtheria Vaccine.....II-58
Tdap – A Vaccine for Tetanus, Diphtheria and Pertussis.....II-58
Measles.....II-58
1$100
   Live, Attenuated (Freeze-Dried) Measles Vaccine.....II-59
Mumps.....II-59
MMR – A Combination Vaccine for Measles, Mumps and Rubella.....II-59
Side Effects of MMR Vaccine.....II-59
1$100
   Polio & Vaccines.....II-60
Influenza Vaccines.....II-60
Hepatitis B Vaccine.....II-60
1$100
   HPV Infection Vaccines.....II-61
HIV Vaccines – Research Clipped by Lack of Funds.....II-61
1$100
   Emergent Begins Phase I/II Clinical Studies of AIG for Anthrax Treatment.....II-62
Novartis Initiates Phase IIb Clinical Trials of Albuferon®.....II-62
Schering-Plough Concludes Phase III Trials for INTRON A® Plus REBETOL™ Combination
  Therapy.....II-62
1$100
   Progenics Advances Research on New Antibody Therapy for HIV.....II-63
Forest Labs Announces Encouraging Phase III Results of Ceftaroline.....II-63
Pharmasset Completes Phase 1a Trial of PSI-7851, Initiates Phase1b Study.....II-63
1$100
   Roche Announces Positive Results of PEGASYS/ COPEGUS Combination Therapy.....II-64
Novartis Announces Phase III Results of Menveo® Vaccine.....II-64
Discovery Laboratories Announces Pre-Clinical Results of SURFAXIN®.....II-64
1$100
   Emergent Commences Phase II Clinical Study of Typhoid Vaccine.....II-65
Enanta Begins Phase I Trial of EDP-322, the First MRSA-Active Bicyclolide.....II-65
Roche, Pharmasset, InterMune Being Oral Anti-Virals Dual-Combination Study.....II-65
1$100
   ANRS, Pharmasset, Gilead Initiate Clevudine + Viread® Clinical Trials.....II-661$100
   Rx Africa (Ethiopia) to Introduce Generic Pharmaceuticals.....II-67
Destiny Pharma Develops New Metallo-Porphyrin Anti-Bacterial Drug.....II-67
Galderma Laboratories Launches EpiduoTM Gel.....II-67
Ranbaxy Rolls Out Generic Valtrex.....II-67
1$100
   Glenmark Introduces Onabet Topical Antifungal Cream.....II-68
MIT Scientists Develop a New Antibiotic, Rhodostreptomycin.....II-68
Watson Pharma Introduces Biaxin XL’s Generic Version.....II-68
Taisho Toyama Pharmaceutical Rolls Out Zosyn®.....II-68
1$100
   GSK Launches ALTARGO® in the UK.....II-69
Toyama Launches New Garenoxacin Quinolone Antibiotic.....II-69
Wockhardt to Introduce Cefprozil in the US.....II-69
MSD India Launches Invanza in India.....II-69
1$100
   Macrolide Antibiotic Developed in the US.....II-70
University of Michigan Devises NMR Spectroscopy for Antibiotics.....II-70
Glycopeptide-Cephalosporin Antibiotics Developed in the US.....II-70
1$100
   Merck Merges with Schering-Plough.....II-71
Beactica and Cubist Sign Agreement.....II-71
Akela Pharma Acquires Nventa Biopharmaceuticals.....II-71
GSK and Pfizer Establish New JV for Developing Anti-HIV Drugs.....II-71
1$100
   Evotec and Cubist Ink Research Pact for Fragment-Based Drug Discovery.....II-72
Grindeks Commences Production of Anti-flu Drug, Rimantadine-Grindeks.....II-72
Galapagos Expands Partnership with GSK.....II-72
1$100
   GSK Acquires Stiefel.....II-73
The Medicines Company Acquires Targanta.....II-73
Tibotec Signs Licensing and Partnership Deal with Gilead.....II-73
1$100
   Abbott Buys Ibis Biosciences.....II-74
Elder and Strides on Expansion Mode.....II-74
Kemin Industries Acquires Amalyte Pharmaceuticals.....II-74
Valeant Pharmaceuticals International Acquires EMO-FARM.....II-74
1$100
   Pfizer Inks Agreements with Claris Lifesciences and Aurobindo Pharma.....II-75
moksha8 Extends Partnership with Roche.....II-75
Akorn Signs Agreement with Eli Lilly and Company.....II-75
Access Pharmaceuticals Acquires MacroChem.....II-75
1$100
   Vertex Pharmaceuticals Acquires ViroChem Pharma.....II-76
sanofi-aventis Acquires Laboratorios Kendrick.....II-76
DSM Enters into Joint Venture with North China Pharmaceutical Group.....II-76
1$100
   NovaBay Inks Agreement with Medical University of Innsbruck.....II-77
Tibotec Collaborates with Global Alliance for TB Drug Development.....II-77
DSM Aired Plans to Divest DSM Deretil.....II-77
1$100
   3i to Buy Alpharma Unit.....II-78
Three Rivers Acquires Infergen® HCV Drug from Valeant.....II-78
ULL Establishes New Antibiotics Unit in Himachal Pradesh.....II-78
Biocat to Expand Presence in the Indian Market.....II-78
Ranbaxy Signs Agreement with Merck.....II-78
1$100
   Zydus Acquires Controlling Interest in Simayla Pharmaceuticals.....II-79
Novartis to Acquire Protez.....II-79
Marksans Acquires Relonchem.....II-79
Orchid Signs Licensing Agreement with Merck.....II-79
1$100
   Forest and Novexel Sign Licensing Agreement.....II-80
Sanofi-aventis Collaborates with Novozymes.....II-80
Janssen-Cilag International Obtains Marketing Authorization for INTELENCETM.....II-80
1$100
   Nastech Pharmaceutical Company Changes Name to MDRNA.....II-81
Galderma Laboratories Acquires CollaGenex Pharmaceuticals.....II-81
Foamix Inks Licensing Deal with Ramot for Organo-Boron Anti-fungal Molecules.....II-81
Emergent BioSolutions Forges Joint Venture with the University of Oxford.....II-81
1$100
   Emergent BioSolutions to Acquire Recombinant Flu Vaccine, FluBlok®.....II-82
AstraZeneca Acquires Arrow Therapeutics.....II-82
1$100
   Cubist Submits INDs for CB-182,804 and CB-183,315.....II-83
SRI International Partners with Blanca Pharmaceuticals to Develop Antibiotics.....II-83
1$100
   Allergan Acquires Esprit Pharma.....II-84
GSK And Anacor Team Up for Boron Chemistry-Based Antibiotics and Antivirals.....II-84
J&J PRD Seeks FDA Approval for Doripenem Antibiotic.....II-84
J&JPRD Seeks FDA Approval for Ceftobiprole.....II-84
1$100
   GSK to Cease Sale of Amprenavir Protease Inhibitor.....II-85
Iroko Bags Canadian Rights to Vancocin®.....II-85
AstraZeneca Purchases Biologics Production Facility from DSM Biologics.....II-85
Depomed Expands Agreement with Watson Pharmaceuticals.....II-85
Depomed Terminates Agreement with Esprit Pharma.....II-85
Phylogica and Dynamic Microbials Inks Agreement.....II-85
1$100
   Pharmasset Collaborates with University of Cincinnati.....II-86
Homeland Safety International Acquires Majority Stake in PLC Marketing.....II-86
Ecopia and Caprion Merge to Form Thallion Pharmaceuticals.....II-86
1$100
   FDA Clears Extended Therapy with INTRON A in Chronic HCV Patients.....II-87
Abbott Obtains EC Approval for Kaletra® in Treating HIV Patients.....II-87
Tibotec Gets EC Clearance for PREZISTA® in Treating HIV Patients.....II-87
Health Canada Approves Anti-HIV-1 Drug, ISENTRESS®.....II-87
Mylan Receives FDA Approval for Linezolid 600 mg Tablets.....II-87
1$100
   Rottapharm/Madaus Obtains Clearance to Market ProQuin XR in Sweden.....II-88
MiddleBrook Obtains NDA Approval for MOXATAG™.....II-88
Tibotec Pharmaceuticals Obtains US FDA Approval for PREZISTA®.....II-88
Wyeth Receives an Approvable Letter from US FDA for TYGACIL®.....II-88
Astellas Pharma Receives Approval from US FDA for MYCAMINE®.....II-88
1$100
   Cubist Pharmaceuticals Receives Health Canada Approval for CUBICIN®.....II-89
Cubist Receives EC Approval for Extended Use of Cubicin®.....II-89
GSK Receives Approval for ALTARGO® in Europe.....II-89
1$100
   Cubist Gains Approval for CUBICIN in Taiwan and South Korea.....II-901$100
   Abbott Laboratories (USA).....II-91
Alcon Pharmaceuticals Ltd. (Switzerland).....II-91
1$100
   Astellas Pharma, Inc. (Japan).....II-92
AstraZeneca PLC (UK).....II-92
1$100
   Bayer HealthCare AG (Germany).....II-93
Bristol-Myers Squibb Co. (USA).....II-93
1$100
   Boehringer Ingelheim (Germany).....II-94
Cubist Pharmaceuticals, Inc. (USA).....II-94
1$100
   Daiichi Sankyo Company, Limited (Japan).....II-95
Eli Lilly and Company (USA).....II-95
1$100
   Gilead Sciences, Inc. (USA).....II-96
GlaxoSmithKline Plc (UK).....II-96
1$100
   F. Hoffmann-La Roche, Ltd. (Switzerland).....II-97
Johnson & Johnson (USA).....II-97
1$100
   Merck & Co., Inc (USA).....II-98
Novartis AG (Switzerland).....II-98
1$100
   Pfizer, Inc. (USA).....II-991$100
   Sanofi-Aventis SA (France).....II-100
Table 14: The below table exhibits worldwide vaccines sales of the company for the year 2008: (includes corresponding Graph/Chart).....II-100
1$350
   Wyeth Pharmaceuticals, Inc. (USA).....II-1011$100
   Anti-infectives by Region:.....II-102
Table 15: World Recent Past, Current & Future Analysis for Anti-Infectives by Geographic Region - US, Japan, Europe, and Rest of World Markets Independently Analyzed by Annual Revenues in US$ Million for the Years 2006 through 2015 (includes corresponding Graph/Chart).....II-102
1$350
   Table 16: World 10-Year Perspective for Anti-Infectives by Geographic Region - Percentage Breakdown of Dollar Revenues for the US, Japan, Europe, and Rest of World Markets for 2006, 2009 & 2015 (includes corresponding Graph/Chart).....II-1031$350
   Anti-Infectives by Therapeutic Class:.....II-104
Table 17: World Recent Past, Current & Future Analysis for Anti-Infectives by Therapeutic Class - Antibacterials, Antivirals, Antifungals, and Others Markets Independently Analyzed by Annual Revenues in US$ Million for the Years 2006 through 2015 (includes corresponding Graph/Chart).....II-104
1$350
   Table 18: World 10-Year Perspective for Anti-Infectives by Therapeutic Class - Percentage Breakdown of Dollar Revenues for Antibacterials, Antivirals, Antifungals, and Others Markets for 2006, 2009 & 2015 (includes corresponding Graph/Chart).....II-1051$350
   Anti-bacterials by Region:.....II-106
Table 19: World Recent Past, Current & Future Analysis for Anti-Bacterials by Geographic Region - US, and Rest of World Markets Independently Analyzed by Annual Revenues in US$ Million for the Years 2006 through 2015 (includes corresponding Graph/Chart).....II-106
1$350
   Table 20: World 10-Year Perspective for Anti- Bacterials by Geographic Region - Percentage Breakdown of Dollar Revenues for the US and Rest of World Markets for 2006, 2009 & 2015 (includes corresponding Graph/Chart).....II-1071$350
   Anti-bacterials By Drug-Class:.....II-108
Table 21: World Recent Past, Current & Future Analysis for Anti-Bacterials by Drug Class - Cephalosporins, Penicillins, Fluoroquinolones, Macrolides, and Others Markets Independently Analyzed by Annual Revenues in US$ Million for the Years 2006 through 2015 (includes corresponding Graph/Chart).....II-108
1$350
   Table 22: World 10-Year Perspective for Anti-Bacterials by Drug Class - Percentage Breakdown of Dollar Revenues for Cephalosporins, Penicillins, Fluoroquinolones, Macrolides, and Others Markets for 2006, 2009 & 2015 (includes corresponding Graph/Chart).....II-1091$350
   Table 23: World Recent Past, Current & Future Analysis for Cephalosporins by Geographic Region - US and Rest of World Markets Independently Analyzed by Annual Revenues in US$ Million for the Years 2006 through 2015 (includes corresponding Graph/Chart).....II-1101$350
   Table 24: World 10-Year Perspective for Cephalosporins by Geographic Region - Percentage Breakdown of Dollar Revenues for the US and Rest of World Markets for 2006, 2009 & 2015 (includes corresponding Graph/Chart).....II-1111$350
   Table 25: World Recent Past, Current & Future Analysis for Penicillins by Geographic Region - US and Rest of World Markets Independently Analyzed by Annual Revenues in US$ Million for the Years 2006 through 2015 (includes corresponding Graph/Chart).....II-1121$350
   Table 26: World 10-Year Perspective for Penicillins by Geographic Region - Percentage Breakdown of Dollar Revenues for the US and Rest of World Markets for 2006, 2009 & 2015 (includes corresponding Graph/Chart).....II-1131$350
   Table 27: World Recent Past, Current & Future Analysis for Fluoroquinolones by Geographic Region - US and Rest of World Markets Independently Analyzed by Annual Revenues in US$ Million for the Years 2006 through 2015 (includes corresponding Graph/Chart).....II-1141$350
   Table 28: World 10-Year Perspective for Fluoroquinolones by Geographic Region - Percentage Breakdown of Dollar Revenues for the US and Rest of World Markets for 2006, 2009 & 2015 (includes corresponding Graph/Chart).....II-1151$350
   Table 29: World Recent Past, Current & Future Analysis for Macrolides by Geographic Region - US and Rest of World Markets Independently Analyzed by Annual Revenues in US$ Million for the Years 2006 through 2015 (includes corresponding Graph/Chart).....II-1161$350
   Table 30: World 10-Year Perspective for Macrolides by Geographic Region- Percentage Breakdown of Dollar Revenues for the US and Rest of World Markets for 2006, 2009 & 2015 (includes corresponding Graph/Chart).....II-1171$350
   Table 31: World Recent Past, Current & Future Analysis for Other Anti-bacterials by Geographic Region - US and Rest of World Markets Independently Analyzed by Annual Revenues in US$ Million for the Years 2006 through 2015 (includes corresponding Graph/Chart).....II-1181$350
   Table 32: World 10-Year Perspective for Other Anti-bacterials by Geographic Region - Percentage Breakdown of Dollar Revenues for the US and Rest of World Markets for 2006, 2009 & 2015 (includes corresponding Graph/Chart).....II-1191$350
   A. Market Analysis.....III-1
HIV Market Perspective in the US.....III-1
HIV/AIDS - Prevalence.....III-1
1$75
   Homosexual Males – A Significant Risk Group for HIV Infections.....III-2
Women – A High Risk Group for HIV/AIDS.....III-2
African-Americans - The Leading High Risk Ethnic Group for HIV Infection.....III-2
Latinos - The Second Major Ethnic Risk Group for HIV Infection.....III-2
An Overview of Sexually Transmitted Diseases (STDs).....III-2
1$75
   Regulatory Environment.....III-3
Product Innovations/Introductions.....III-3
1$75
   Strategic Corporate Developments.....III-47$325
   FDA Regulations And Approvals.....III-111$75
   Focus on Select Players.....III-128$375
   B. Market Analytics.....III-20
Table 33: US Recent Past, Current & Future Analysis for Anti-Infectives Market Analyzed with Annual Sales Revenues in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart).....III-20
1$200
   Table 34: US Recent Past, Current & Future Analysis for Anti-Bacterials Market by Drug Class - Cephalosporins, Penicillins, Fluoroquinolones, Macrolides, and Others Markets Analyzed by Annual Revenues in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart).....III-211$200
   Table 35: US 10-year Perspective for Anti-Bacterials Market by Drug Class - Percentage Breakdown of Dollar Revenues for Cephalosporins, Penicillins, Fluoroquinolones, Macrolides, and Others Markets for Years 2006, 2009 & 2015 (includes corresponding Graph/Chart).....III-221$200
   A. Market Analysis.....III-23
Infectious Disease Market Witnessing Mixed Fortunes in Japan.....III-23
HIV Infection Prevalence – One of the Lowest Worldwide.....III-23
1$75
   Hepatitis C Prevalence – Widespread and Driving the Hepatitis C Drugs
  Market.....III-24
Table 36: Leading Hepatitis C Anti-viral Products in Japan (2008(E)): Percentage Share Breakdown for PEG-Intron, Pegasys, Intron A, Advaferon, Sumiferon, Feron, and Others (includes corresponding Graph/Chart).....III-24
1$200
   Product Innovations/Introductions.....III-25
Focus on Select Players.....III-25
3$175
   B. Market Analytics.....III-28
Table 37: Japanese Recent Past, Current & Future Analysis for Anti-Infectives Market - Annual Revenues in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart).....III-28
1$200
   A. Market Analysis.....III-29
Strategic Corporate Developments.....III-29
3$175
   B. Market Analytics.....III-32
Table 38: European Recent Past, Current & Future Analysis for Anti-Infectives Market by Geographic Region - France, Germany, Italy, UK, Spain, and Rest of Europe Markets Analyzed by Annual Revenues in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart).....III-32
1$200
   Table 39: European 10-year Perspective for Anti-Infectives Market by Geographic Region - Percentage Breakdown of Dollars Revenues for France, Germany, Italy, UK, Spain, and Rest of Europe Markets for Years 2006, 2009 & 2015 (includes corresponding Graph/Chart).....III-331$200
   A. Market Analysis.....III-34
France - The Largest Market for Anti-Infectives in Europe.....III-34
Antibiotics Use Takes A Dip, As Regulatory Authorities’ Efforts Pays Off.....III-34
Strategic Corporate Development.....III-34
1$75
   Focus on Select Player.....III-35
Sanofi-Aventis SA.....III-35
Table 40: The below table exhibits worldwide vaccines sales of the company for the year 2008: (includes corresponding Graph/Chart).....III-35
1$200
   B. Market Analytics.....III-36
Table 41: French Recent Past, Current & Future Analysis for Anti-Infectives Market - Annual Revenues in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart).....III-36
1$200
   A. Market Analysis.....III-37
Strategic Corporate Development.....III-37
Focus on Select Players.....III-37
2$125
   B. Market Analytics.....III-39
Table 42: German Recent Past, Current & Future Analysis for Anti-Infectives Market - Annual Revenues in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart).....III-39
1$200
   Market Analysis.....III-40
Table 43: Italian Recent Past, Current & Future Analysis for Anti-Infectives Market - Annual Revenues in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart).....III-40
1$200
   A. Market Analysis.....III-41
Infectious Diseases – A Quick Primer.....III-41
Table 44: Number of new Cases, and Deaths due to Infectious Disorders in UK (2006): Breakdown by Infection Type (includes corresponding Graph/Chart).....III-41
Research and Development of New Anti-Infectives.....III-41
1$200
   Table 45: Number of New Anti-Infectives Approved in UK (2003-2007): Breakdown by Therapeutic Class - Anti-Virals and Anti-Bacterials.....III-42
Impediments to the Development of New Anti-infectives.....III-42
Scientific Barriers.....III-42
Economic Barriers.....III-42
Regulatory Barriers.....III-42
1$200
   HIV/AIDS Prevalence – On the Rise.....III-43
Drug Resistant HIV Strains - Incidence Rising.....III-43
STD – Rising Incidence Poses Health Risks.....III-43
1$75
   Product Innovations/Introductions.....III-44
Strategic Corporate Developments.....III-44
3$125
   Focus on Select Players.....III-471$75
   B. Market Analytics.....III-48
Table 46: UK Recent Past, Current & Future Analysis for Anti-Infectives Market - Annual Revenues in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart).....III-48
1$200
   Market Analysis.....III-49
Table 47: Spanish Recent Past, Current & Future Analysis for Anti-Infectives Market - Annual Revenues in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart).....III-49
1$200
   A. Market Analysis.....III-50
Focus on Select Market.....III-50
Russia – Leading the Prevalence of HIV/AIDS.....III-50
Acute Drug Supply Shortages Risk Lives HIV Victims.....III-50
Strategic Corporate Developments.....III-50
2$125
   Focus on Select Players.....III-522$125
   B. Market Analytics.....III-54
Table 48: Rest of Europe Recent Past, Current & Future Analysis for Anti-Infectives Market - Annual Revenues in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart).....III-54
1$200
   A. Market Analysis.....III-55
Focus on Select Markets.....III-55
Canada.....III-55
HIV/AIDS Prevalence.....III-55
Asia-Pacific.....III-55
HIV/AIDS Prevalence.....III-55
1$75
   HIV Infection Rising Among Male.....III-56
Australia.....III-56
HIV/AIDS Prevalence.....III-56
Chronic Hepatitis C Prevalence.....III-56
1$75
   Bangladesh.....III-57
HIV/AIDS Prevalence.....III-57
Cambodia.....III-57
HIV/AIDS Prevalence.....III-57
China.....III-57
HIV/AIDS Prevalence.....III-57
1$75
   Antibiotics Market.....III-58
Antibiotics Manufacturing.....III-58
Carbapenem Antibiotics Hold Great Potential.....III-58
China Represents a Major Market for Hepatitis B Therapies.....III-58
1$75
   India.....III-59
HIV/AIDS Prevalence.....III-59
Not-for-Profit Organizations Active in HIV/AIDS Control and Prevention.....III-59
1$75
   AIDS Control Programs for Rural Youths in India.....III-60
Anti-Infectives Market Experiencing Double- Digit Growth.....III-60
Table 49: Pharmaceutical Market in India (2007): Percentage Market Share Breakdown by Therapeutic Class (includes corresponding Graph/Chart).....III-60
1$200
   Competition.....III-61
Top 5 Drug Producers in India, and their Major Products.....III-61
Injectable Antibiotics Demonstrate Robust Growth.....III-61
New Initiative to Develop Novel Antibiotic Molecules.....III-61
Major Players - Hepatitis B Vaccines.....III-61
1$75
   Product Innovations/Introductions.....III-621$75
   Strategic Corporate Developments.....III-633$175
   Focus on Select Players.....III-662$125
   B. Market Analytics.....III-68
Table 50: Rest of World Recent Past, Current & Future Analysis for Anti-Infectives Market - Annual Revenues in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart).....III-68
1$200
   Table 51: Rest of World Recent Past, Current & Future Analysis for Anti-Bacterials Market by Drug Class - Cephalosporins, Penicillins, Fluoroquinolones, Macrolides, and Others Markets Analyzed by Annual Revenues in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart).....III-691$200
   Table 52: Rest of World 10-year Perspective for Anti-Bacterials Market by Drug Class - Percentage Breakdown of Dollars Revenues for Cephalosporins, Penicillins, Fluoroquinolones, Macrolides, and Others Markets for Years 2006, 2009 & 2015 (includes corresponding Graph/Chart).....III-701$200
    
 
 


Sales queries: Sales@StrategyR.com
Research queries: Info411@StrategyR.com